Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.73 -0.01 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Karyopharm Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 146 | 157 | 210 | 108 | 41 |
Cost Of Goods | 5 | 5 | 3 | 3 | 2 |
Gross Profit | 141 | 152 | 206 | 105 | 38 |
Selling & Adminstrative & Depr. & Amort Expenses | 271 | 294 | 305 | 277 | 228 |
Income After Depreciation & Amortization | -130 | -142 | -98 | -172 | -189 |
Non-Operating Income | 11 | 2 | 1 | 3 | 5 |
Interest Expense | 24 | 25 | 26 | 27 | 16 |
Pretax Income | -143 | -165 | -124 | -196 | -200 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -143 | -165 | -124 | -196 | -200 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -143 | -165 | -124 | -196 | -200 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -132 | -142 | -95 | -161 | -182 |
Depreciation & Amortization (Cash Flow) | -3 | 1 | 3 | 10 | 7 |
Income After Depreciation & Amortization | -130 | -142 | -98 | -172 | -189 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 114.22 | 81.87 | 75.22 | 72.04 | 61.96 |
Diluted EPS Before Non-Recurring Items | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 |
Diluted Net EPS (GAAP) | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 |
Fiscal Year end for Karyopharm Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 42.79 | 33.13 | 33.75 | 36.01 | 37.58 |
Cost Of Goods | 1.47 | 1.91 | 1.49 | 0.91 | 1.19 |
Gross Profit | 41.32 | 31.22 | 32.26 | 35.10 | 36.39 |
SG&A, R&D, and Dept/Amort Expenses | 69.44 | 64.98 | 70.07 | 66.36 | 65.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | -28.12 | -33.76 | -37.81 | -31.26 | -29.57 |
Non-Operating Income | 60.93 | 2.35 | 2.31 | 2.84 | 2.85 |
Interest Expense | 8.95 | 5.88 | 6.21 | 6.07 | 5.78 |
Pretax Income | 23.86 | -37.29 | -41.71 | -34.49 | -32.50 |
Income Taxes | 0.07 | 0.07 | 0.13 | 0.01 | 0.13 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 23.79 | -37.36 | -41.84 | -34.51 | -32.63 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 23.79 | -37.36 | -41.84 | -34.51 | -32.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 154.43 | 115.45 | 114.78 | 114.40 | 114.21 |
Diluted EPS Before Non-Recurring Items | -0.20 | -0.32 | -0.36 | -0.30 | -0.29 |
Diluted Net EPS (GAAP) | -0.20 | -0.32 | -0.36 | -0.30 | -0.29 |